Correction: Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia. uri icon

Overview

authors

  • Zhang, Qi
  • Riley-Gillis, Bridget
  • Han, Lina
  • Jia, Yannan
  • Lodi, Alessia
  • Zhang, Haijiao
  • Ganesan, Saravanan
  • Pan, Rongqing
  • Konoplev, Sergej N
  • Sweeney, Shannon R
  • Ryan, Jeremy A
  • Jitkova, Yulia
  • Dunner, Kenneth
  • Grosskurth, Shaun E
  • Vijay, Priyanka
  • Ghosh, Sujana
  • Lu, Charles
  • Ma, Wencai
  • Kurtz, Stephen
  • Ruvolo, Vivian R
  • Ma, Helen
  • Weng, Connie C
  • Ramage, Cassandra L
  • Baran, Natalia
  • Shi, Ce
  • Cai, Tianyu
  • Davis, Richard Eric
  • Battula, Venkata L
  • Mi, Yingchang
  • Wang, Jing
  • DiNardo, Courtney D
  • Andreeff, Michael
  • Tyner, Jeffery W
  • Schimmer, Aaron
  • Letai, Anthony
  • Padua, Rose Ann
  • Bueso-Ramos, Carlos E
  • Tiziani, Stefano
  • Leverson, Joel
  • Popovic, Relja
  • Konopleva, Marina

publication date

  • April 1, 2022

Identity

PubMed Central ID

  • PMC8975942

Scopus Document Identifier

  • 85127391782

Digital Object Identifier (DOI)

  • 10.1038/s41392-022-00958-4

PubMed ID

  • 35365596

Additional Document Info

volume

  • 7

issue

  • 1